Inhibrx Biosciences, Inc.
INBX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002007919
In the last 90 days, Inhibrx Biosciences, Inc. insiders filed 6 open-market purchases and 2 sales; 162 institutions reported holding it in 13F filings for Q2 2026, worth $1.36B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q2 2022
Institutional positions in Inhibrx Biosciences, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 100
- +4 vs. Q1 2022
- Shares held
- 26.2M
- +1.63M (+6.6%) vs. Q1 2022
- Total value
- $297.3M
- −$249.6M (−45.6%) vs. Q1 2022
- New holders
- 18
- 40 more added
- Sold out
- 14
- 25 more reduced
3 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INBX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 162 | $1.36B |
| Q1 2026 | 135 | $854.6M |
| Q4 2025 | 138 | $1.01B |
| Q3 2025 | 102 | $353.6M |
| Q2 2025 | 89 | $148.9M |
| Q1 2025 | 92 | $151.0M |
| Q4 2024 | 101 | $171.9M |
| Q3 2024 | 96 | $139.3M |
| Q2 2024 | 88 | $137.9M |
| Q1 2024 | 126 | $1.34B |
| Q4 2023 | 126 | $1.54B |
| Q3 2023 | 111 | $716.1M |
| Q2 2023 | 107 | $935.2M |
| Q1 2023 | 108 | $691.6M |
| Q4 2022 | 116 | $886.0M |
| Q3 2022 | 102 | $512.2M |
| Q2 2022 | 100 | $297.3M |
| Q1 2022 | 99 | $548.0M |
| Q4 2021 | 101 | $1.01B |
| Q3 2021 | 66 | $681.6M |
| Q2 2021 | 61 | $538.8M |
| Q1 2021 | 55 | $326.3M |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Inhibrx Biosciences, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Adage Capital Partners GP, L.L.C. | 0 | $0 | 0.00% | −1,154,348−100.0% | Sold out |
| Tri Locum Partners LP | 0 | $0 | 0.00% | −406,733−100.0% | Sold out |
| Rafferty Asset Management, LLC | 0 | $0 | 0.00% | −95,034−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −32,343−100.0% | Sold out |
| Voloridge Investment Management, LLC | 0 | $0 | 0.00% | −31,466−100.0% | Sold out |
| Vident Investment Advisory, LLC | 0 | $0 | 0.00% | −26,940−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −15,247−100.0% | Sold out |
| RS Crum Inc. | 0 | $0 | 0.00% | −14,659−100.0% | Sold out |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −12,805−100.0% | Sold out |
| ProShare Advisors LLC | 0 | $0 | 0.00% | −9,273−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −9,135−100.0% | Sold out |
| Leonteq Securities AG | 0 | $0 | 0.00% | −360−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −85−100.0% | Sold out |
| Covestor Ltd | 0 | $0 | 0.00% | −9−100.0% | Sold out |
| Parametric Portfolio Associates LLC | – | – | – | – | Not filed |
| IndexIQ Advisors LLC | – | – | – | – | Not filed |
| Amalgamated Financial Corp. | – | – | – | – | Not filed |